Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-06
2007-02-06
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S455000, C536S023100, C536S024320, C536S024500
Reexamination Certificate
active
09896692
ABSTRACT:
Disclosed are synthetic oligonucleotides having a nucleotide sequences specifically complementary to nucleotides 324 to 345 of a conserved gag region of the HIV-1 genome, the oligonucleotide consisting of 21 nucleotides which are linked via phosphorothioate internucleotide linkages. Also disclosed are methods for inhibiting and treating HIV-1 and HIV-2 infection.
REFERENCES:
patent: 4309404 (1982-01-01), DeNeale et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4556552 (1985-12-01), Porter et al.
patent: 4704295 (1987-11-01), Porter et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5470702 (1995-11-01), Hovanessian et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5627277 (1997-05-01), Cohen et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5652356 (1997-07-01), Agrawal
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 6645943 (2003-11-01), Agrawal et al.
patent: 2002/0168340 (2002-11-01), Agrawal
patent: WO 94/08004 (1994-04-01), None
patent: WO 95/11813 (1995-07-01), None
patent: WO96/12497 (1996-05-01), None
patent: WO 97/06662 (1997-02-01), None
patent: WO 98/40058 (1998-09-01), None
Agrawal, S. et al. Molecular Med. Today, vol. 6, pp. 72-81 (2000).
S. Crooke. Antisense Res and Application, Chapter 1, pp. 1-50 (S. Crooke, ed. Springer-Verlag, Publi.) (1998).
Chirila, T. et a. Biomaterials, vol. 23, pp. 321-342 (2002).
Branch, A. Trends in Biochem. Sci. vol. 23, pp. 45-50 (1998).
Pihl-Carey, K. BioWorld Today, vol. 10, pp. 1-2 (1999).
Peracchi, A. et al. Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Milner et al. (1977) “Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays,”Nature Biotech.15:537-541.
Wickstrom (1986) “Oligodeoxynucletide Stability in Subcellular Extracts and Culture Media,”J. Biochem. Biophys. Meth.13:97-102.
Zamecnik et al. (1986) “Inhibition of Replication and Expression of Human T-cell Lymphotropic Virus Type III in Cultured Cells by Exogenous Synthetic Oligonucleotides Complementary to Viral RNA,”Proc. Natl. Acad. Sci. USA83:4143-4147.
Agrawal et al. (1987) “Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation,”Tetrahedron. Lett.28 (31):3539-3542.
Agrawal et al. (1988) Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus,Proc. Natl. Acad. Sci. USA85:7079-7083.
Goodchild et al. (1988) “Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides,”Proc. Natl. Acad. Sci. USA85:5507-5511.
Matsukura et al. (1988) “Synthesis of Phosphorothioate Analogues of Oligodeoxyribonucleotides and Their Antivirual Activity Against Human Immunodeficiency Virus (HIV),”Gene72:343-347.
Sarin et al. (1988) “Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates,”Proc. Acad. Sci. USA85:7448-7451.
Agrawal et al. (1989) “Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and Their Phosphorothioate Analogues,”Proc. Natl. Acad. Sci. USA86:7790-7794.
Matsukura et al. (1989) “Regulation of Viral Expression of Human Immunodeficiency VirusIn Vitroby an Antisense Phosphorotioate Oligodeoxynucleotide Againstrev(art/trs) In Chronically Infected Cells,”Proc. Natl. Acad. Sci. USA86:4244-4248.
Gennaro (ed.) (1990)Remington's Pharmaceutical Sciences(18thEd.) Mack Publishing Co., Easton, PA.
Uhlmann et al. (1990) “Antisense Oligonucleotides: A New Therapeutic Principle,”Chem. Rev.90:543-583.
Agrawal (1991) inProspects for Antisense Nucleic Acid Therapy of Cancer and AIDS, (Wickstron, ed.) Wiley-Liss, Inc., pp. 143-158.
Harrison et al. (1991) inRNA Tumor Viruses(Coffin et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harson, NY, p. 235).
Vickers et al. (1991) “Inhibition of HIV-LTR Gene Expression by Oligonucleotides Targeted to the TAR Element,”Nucleic Acids Res.19:3359-3368.
Agrawal (1992) “Antisense Oligonucleotides as Antiviral Agents,”Trends in Biotechnology10:152-158.
Agrawal et al. (1992) “Cellular Uptake and Anti-HIV Activity in Oligonucleotides and Their Analogs,”Gene Regulation: Biology of Antisense RNA and DNA(Erickson and Izant, eds.) Raven Press Ltr., New York, pp. 273-283.
Matsukura et al. (1992) “A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application,”Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wiley-Liss, Inc., pp. 159-178.
Tang et al. (1993) “Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity,”Nucleic Acids Res.20:2729-2735.
Brown (1994) “A Brief History of Oligonucleotide Synthesis. Protocols for Oligonucleotides and Analogs,”Methods in Molecular Biology20: 1-8.
Froehler (1994) “Oligodeoxynucleotide Synthesis,”Methods in Molecular Biology20:63-80.
Sonveaux (1994) “Protecting Groups in Oligonucleotide Synthesis,”Methods in Molecular Biology26:1-72.
Agrawal et al. (1995) “Tissue Distribution andIn VivoStability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration,”Biochem. Pharmacol.50(4):571-576.
Iyer et al. (1995) “A Novel Nucleoside Phosphoroamidite Synthon Derived From1R,2S-Ephedrine,”Tetrahedron Asymmetry6:1051-1054.
Krieg et al. (1995) “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation,”Nature374:546-549.
Gewirtz et al. (1996) “Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise,”Proc. Natl. Acad. Sci. USA93:3161-3163.
Rojanasakul (1996) “Antisense Oligonucleotide Therapeutics,”Adv. Drug Del. Rev.vol. 18:115-131.
Zhao et al. (1996) “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation,”Biochem. Pharmacol.51(2):173-182.
Zhang et al. (1996) “Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleosider Phosphorothioate in Rats After Intravenous Administration,”J. Pharmacol. Expt. Thera.278:1-5.
Agrawal, et al. (1992) “GEM*91—An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS”,Antisense Res. Dev.2:261-266.
Agrawal et al. (1994) “Potential for HIV-1 Treatment with Antisense Oligonucleotides”,J. Biotech. in Healthcare,1(2):167-182.
Agrawal, et al. (1995) “Pharmacokinetics of Antisense Oligonucleotides”,Clin. Pharmacokinet.28(1):7-16.
Agrawal (1996) “Preface” InMethods in Molecular Medicine: Antisense Therapeutics(Agrawal,ed.) pp. v-vii.
Agrawal, et al. (1998) “Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals”, inHandbook of Experimental Pharmacology, vol. 131: Antisense Research and Application, Springer-Verlag, pp. 525-543.
Agrawal (1999) “Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides,”Biochemica et Biophysica Acta1489:53-68.
Beaucage (1993) “Oligodeoxyribonucleotides Synthesis”Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotides and Analogs, (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 33-61.
Brown (1993) “A Brief History of Oligonucleotide Synthesis” inMethods in Molecular Biology, vol. 20: Protocols for Oligonucleotides and Analogs, pp. 1-17.
Craig et al. (1997) “Patent strategies in the antisense oligonucleotide based therapeutic approach”Exp. Opin. Ther. Patents7(10):1175-1182.
Database CAS Registry(2003), (Date of entry: 1997), Registry No. 193635-63-1.
Froehler (1993) “Oligodeoxynucleotide Synthesis,”Methods in Molecular Biology, vol. 20; Protocols for Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80.
Furdon (1
Idera Pharmaceuticals Inc.
Wilmer Cutler Pickering Hale and Dorr LLP
Zara Jane
LandOfFree
HIV-specific synthetic oligonucleotides and methods of their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-specific synthetic oligonucleotides and methods of their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-specific synthetic oligonucleotides and methods of their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892611